The field of EGFR TKI resistance research has identified many ncRNAs interacting with oncoproteins, which may directly relieve the trigger of downstream signaling in EGFR TKI-resistant lung cancer and thereby reduce drug sensitivity. The gene discussed is EGFR; the disease is lung carcinoma.